novel
approach
modifi
cell
express
viral
marker
elicit
protect
immun
respons
decoy
cellular
vaccin
prevent
diseas
current
explor
approach
entail
util
spike
antigenexpress
nonrepl
cell
carrier
present
immunogen
antigen
call
icel
use
irradi
cell
present
vehicl
viral
antigen
cellular
context
present
viral
protein
recogn
host
immun
system
thu
effici
protect
immun
respons
might
elicit
anoth
advantag
strategi
manufactur
process
scalabl
yield
uniform
cell
product
allow
offtheshelf
frozen
suppli
avail
prevent
engraft
prolifer
cell
administr
cell
irradi
postharvest
abolish
vivo
replic
potenti
specif
immunoreact
protein
express
surfac
irradi
target
icel
util
innov
strategi
viral
antigendisplay
decoy
cell
develop
vaccin
protect
diseas
enabl
deliveri
present
pathogenspecif
protein
express
nativ
conform
host
immun
system
overcom
known
deliveri
conform
ineffici
associ
nucleic
acid
recombin
proteinbas
approach
critic
compon
success
vaccin
develop
develop
pathway
icel
ie
util
modifi
decoy
cell
carri
present
target
antigen
host
immun
system
depict
fig
engin
protein
express
surfac
human
myelogen
leukemia
cell
via
introduct
express
construct
cellular
genom
allow
stabl
express
transgen
stablemodifi
clone
select
profil
express
well
overal
immunogen
potenc
prepar
gmp
master
cell
bank
use
larg
scale
manufactur
irradi
cell
formul
vaccin
product
administ
via
intramuscular
subcutan
inject
cell
line
hlaneg
exquisit
sensit
nkmediat
kill
express
protein
context
nksensit
cell
line
provid
mean
target
activ
innat
driver
host
adapt
immun
respons
immunogen
thu
viral
infect
host
cell
express
antigen
cancer
vaccin
treatment
util
lethal
irradi
cell
express
granulocytemacrophag
colonystimul
factor
gmcsf
previous
demonstr
well
toler
human
clinic
trial
dose
cell
administ
multipl
parenter
rout
treatment
regimen
includ
nine
dose
administr
gmcsf
express
combin
codeliv
autolog
tumor
antigen
shown
elicit
robust
cellular
humor
antitumor
immun
respons
treat
patient
novel
viru
decoy
cellular
vaccin
design
initi
nk
celldriven
immun
activ
ultim
goal
induc
protect
adapt
host
immun
current
underway
preclin
immun
model
previou
effort
develop
respiratori
viru
vaccin
protect
respiratori
syncyti
viru
rsv
sarsrel
diseas
demonstr
potenti
clinic
benefit
elicit
adapt
immun
respons
diseaseexacerb
effect
polar
respons
immun
studi
mice
four
candid
sar
vaccin
vlp
whole
viru
rdnaproduc
spike
protein
led
pulmonari
immunopatholog
upon
challeng
sar
viru
effect
signifi
polar
mice
immun
candid
vaccin
decoy
cell
vaccin
drive
host
cellular
immun
respons
toward
gener
potent
cytotox
cell
immun
major
determin
cellular
entri
pathogenesi
fig
util
pathogenderiv
cellular
immunogen
virusencod
antigen
initi
nkmediat
immun
respons
might
provid
excit
method
produc
novel
vaccin
candid
import
highlight
flexibl
decoy
cell
vaccin
strategi
addit
cell
vaccin
gener
expediti
manner
new
antigen
interest
identifi
thu
success
demonstr
efficaci
current
approach
clinic
trial
would
pave
way
use
decoy
cell
platform
address
larg
number
unmet
medic
need
clinic
seek
protect
popul
viral
parasit
fungal
bacteri
diseas
sorrento
therapeut
fund
discoveri
develop
clinic
suppli
manufactur
vaccin
platform
mention
commun
